Daniel J Zabransky

List of Publications by Citations

19 papers	517 citations	11 h-index	20 g-index
20 ext. papers	650 ext. citations	10.3 avg, IF	2.49 L-index

#	Paper	IF	Citations
19	ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. *Clinical Cancer Research*, **2016**, 22, 993-9	12.9	129
18	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA. *Clinical Biochemistry*, **2015**, 48, 993-8	3.5	77
17	HER2 missense mutations have distinct effects on oncogenic signaling and migration. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E6205-14	11.5	51
16	Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. *Oncotarget*, **2016**, 7, 6281-93	3.3	49
15	MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 17606-11	11.5	46
14	Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple-Negative Breast Cancer. *Clinical Cancer Research*, **2017**, 23, 379-386	12.9	36
13	Whole-Exome Sequencing of Metaplastic Breast Carcinoma Indicates Monoclonality with Associated Ductal Carcinoma Component. *Clinical Cancer Research*, **2017**, 23, 4875-4884	12.9	25
12	TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. *Oncotarget*, **2015**, 6, 44927-40	3.3	24
11	Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. *Journal of Clinical Investigation*, **2019**, 129, 4708-4723	15.9	21
10	NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 11583-8	11.5	17
9	PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. *Breast Cancer Research and Treatment*, **2017**, 162, 451-464	4.4	12
8	Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. *Journal of Clinical Oncology*, **2014**, 32, 1084-6	2.2	7
7	Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. *Oncotarget*, **2015**, 6, 25240-51	3.3	7
6	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. *Journal of Clinical Investigation*, **2021**, 131,	15.9	5
5	Single-Nucleotide Polymorphism Leading to False Allelic Fraction by Droplet Digital PCR. *Clinical Chemistry*, **2017**, 63, 1370-1376	5.5	3
4	Shared genetic and epigenetic changes link aging and cancer.. *Trends in Cell Biology*, **2022**,	18.3	3
3	The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. *Breast Cancer Research and Treatment*, **2019**, 174, 401-412	4.4	2

List of Publications

2	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. *OncoImmunology*, **2021**, 10, 2001159	7.2	1
1	PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model.. *Oncotarget*, **2022**, 13, 373-386	3.3	